Topical Roflumilast 0.3% Cream: An investigational drug for the treatment of plaque psoriasis

A Preapproval Information Exchange (PIE) Webinar sponsored by Arcutis Biotherapeutics.

Plaque psoriasis is associated with significant disease burden. There is an unmet need for topical agents for special areas including the face, genitals, and skin folds.
Roflumilast cream is an investigational drug for the treatment of plaque psoriasis. 
The following will be discussed during the presentation:
• Burden of plaque psoriasis
• Roflumilast product profile and clinical program

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.